SENS-AI
APN Results Bullish

ASPEN PHARMACARE HOLDINGS LIMITED - Reviewed Condensed Group Financial Results for the year ended 30 June 2026 and Cash Dividend Declaration

Aspen Pharmacare Holdings Limited
Full analysis

What this filing means

Aspen's FY2026 results are in line with the guidance given in the August trading statement: normalised EBITDA growth of 14% CER and NHEPS of 801.5 cents inside the 784.4–817.4 cent range. The dividend is raised 10% to 232 cents, and the fresh signal is FY2027 guidance targeting at least R9 billion normalised EBITDA in CER — a figure that was not in the prior trading statement — with Manufacturing EBITDA expected to more than double. The headline HEPS decline of 20% reflects restructuring and impairment costs, not operating deterioration.

Aspen's underlying business did what it told the market to expect for 2026, and the dividend went up. The confusing part is that the standard profit number fell — but that is because of one-off restructuring costs and accounting write-downs, not because the operating business weakened. The company is also saying next year should be materially better, with normalised EBITDA targeted at least R9 billion — that forward target is new information investors will focus on.

Bull case

  • FCF of R3.8bn (pre-dividends) beat the R3.7bn guidance, with operating cash conversion well above the 100% target and capex R2bn lower YoY.
  • FY2027 normalised EBITDA guided to at least R9bn in CER, underpinned by net interest savings of circa R1.2bn.
  • Manufacturing CER normalised EBITDA is expected to more than double that of FY2026 as the primary driver of Group FY2027 EBITDA growth.
  • Commercial Pharmaceuticals revenue grew 5% to R25.4bn in CER, led by strong Mounjaro demand in South Africa.
  • Dividend raised 10% to 232 cents per share, set at 20% of NHEPS and aligned to the Group's capital allocation framework.

Bear case

  • HEPS fell 20% reported and 15% in CER to 630 cents from 792.1 cents, the headline metric the market trades on.
  • R2.3 billion restructuring costs hit HEPS and EPS with future benefits asserted but not quantified in this filing.
  • R2.3 billion intangible impairments from higher discount rates driven by geopolitical and macro conditions expose the group to asset re-rating risk.
  • Manufacturing revenue declined 10% to R9.5bn as the prior mRNA contract fell away; EBITDA recovery only offsets that lost contribution.
  • Heps vs eps: HEPS 630 cents (-20%) vs EPS 596 cents (>100% swing from -243.9c to +596c) due to R2.4bn APAC disposal profit boosting EPS while R2.3bn restructuring costs and R2.3bn impairments hit both. NHEPS 801.5c (+28% CER) is the cleanest operating measure.
View original SENS announcement

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

SENS-AI conclusion

FY2026 results are confirmation rather than a directional surprise: NHEPS of 801.5 cents sits inside the 784.4–817.4 cent guided range, and free cash flow of R3.8 billion marginally cleared R3.7 billion guided. The fresh signal is the FY2027 R9 billion normalised EBITDA target — not in the prior August trading statement — with Manufacturing EBITDA expected to more than double, underpinned by net interest savings of circa R1.2 billion. That is a constructive forward catalyst, not a backward-looking beat. The bear case is real: HEPS fell 20% on R2.3 billion of restructuring costs and R2.3 billion of impairments. So what: FY2026 is confirmed; the market now needs FY2027 to show the R9 billion EBITDA target and Manufacturing doubling are on track.

The FY2027 interim results are where the market will test whether the R9 billion normalised EBITDA target and Manufacturing doubling are tracking as guided.

Evidence from the filing

  • FCF of R3.8bn (pre-dividends) beat the R3.7bn guidance, with operating cash conversion well above the 100% target and capex R2bn lower YoY.

    “Strong free cash flow (before dividends paid) of R3,8 billion was generated, underpinned by an operating cash conversion rate well above the Group's target of 100%, a working capital to revenue ratio of 44% (prior year of 47%) and capital expenditure ending R2 billion lower than the prior year”

  • FY2027 normalised EBITDA guided to at least R9bn in CER, underpinned by net interest savings of circa R1.2bn.

    “The Group is targeting a normalised EBITDA of at least R9 billion in CER”

  • Manufacturing CER normalised EBITDA is expected to more than double that of FY2026 as the primary driver of Group FY2027 EBITDA growth.

    “Manufacturing CER normalised EBITDA is expected to be more than double that of FY 2026 and will be the primary driver of the Group's FY 2027 normalised EBITDA growth”

  • Commercial Pharmaceuticals revenue grew 5% to R25.4bn in CER, led by strong Mounjaro demand in South Africa.

    “Revenue growth of 5% to R25 405 million was led by strong Mounjaro® demand in South Africa. Discontinuation of unprofitable products in China, following execution of the business reshape plan, diluted overall revenue growth”

  • Dividend raised 10% to 232 cents per share, set at 20% of NHEPS and aligned to the Group's capital allocation framework.

    “The Board has declared a gross dividend of 232 cents per ordinary share (2025: 211 cents per share) (or 185,6 cents net of a 20% dividend withholding tax, where this maximum rate of tax applies) which is 20% of normalised headline earnings per share and aligned to the Group's capital allocation framework”

  • HEPS fell 20% reported and 15% in CER to 630 cents from 792.1 cents, the headline metric the market trades on.

    “Headline earnings per share (cents) 630.0 792.1 (20) (15)”

  • R2.3 billion restructuring costs hit HEPS and EPS with future benefits asserted but not quantified in this filing.

    “Aspen initiated several value enhancement and operational efficiency projects across the Group. The related restructuring costs of R2,3 billion negatively impacted headline earnings per share ("HEPS") and earnings per share ("EPS"). These restructuring projects are fundamental to our future success and have already yielded and will yield further substantial sustainable benefits for the Group”

  • R2.3 billion intangible impairments from higher discount rates driven by geopolitical and macro conditions expose the group to asset re-rating risk.

    “Intangible asset impairments were adversely impacted by higher discount rates driven by current geopolitical and macro-economic conditions. These impairments total R2,3 billion and although they have no cash impact do affect EPS. Despite the negative effect of the higher discount rates, brand related intangible assets retain a valuation of more than 45% above carrying amount”

  • Manufacturing revenue declined 10% to R9.5bn as the prior mRNA contract fell away; EBITDA recovery only offsets that lost contribution.

    “Revenue of R9 465 million ended 10% lower due to the absence of the prior period's mRNA contract”
Category
Results
Event posture
Constructive
Published
Sep 2, 2026

More on Aspen Pharmacare Holdings Limited

Aspen Pharmacare Holdings Limited (APN) share price All Aspen Pharmacare Holdings Limited SENS announcements

Related filings